Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation - Concepedia

Concepedia

Publication | Open Access

Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

DOI Full Paper Access

26

Citations

27

References

2013

Year

Adriaan A. van Bodegraven, Nathalie Bravenboer, Birgit I. Lissenberg‐Witte, Gerard Dijkstra, C. Janneke van der Woude, Pieter C M Stokkers, Maurice G. Rüssel, Bas Oldenburg, Marieke Pierik, Jan C. Roos,

Abstract

A 24-month treatment course with risedronate 35 mg once weekly, concomitant with calcium and vitamin D supplementation, in osteopenic Crohn's disease patients improved bone density at lumbar spine. NTR 163 Dutch Trial Register.

References

	Year	Citations

Page 1